跳轉至內容
Merck
  • Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury.

Antithrombin III/SerpinC1 insufficiency exacerbates renal ischemia/reperfusion injury.

Kidney international (2015-06-25)
Feng Wang, Guangyuan Zhang, Zeyuan Lu, Aron M Geurts, Kristie Usa, Howard J Jacob, Allen W Cowley, Niansong Wang, Mingyu Liang
摘要

Antithrombin III, encoded by SerpinC1, is a major anti-coagulation molecule in vivo and has anti-inflammatory effects. We found that patients with low antithrombin III activities presented a higher risk of developing acute kidney injury after cardiac surgery. To study this further, we generated SerpinC1 heterozygous knockout rats and followed the development of acute kidney injury in a model of modest renal ischemia/reperfusion injury. Renal injury, assessed by serum creatinine and renal tubular injury scores after 24 h of reperfusion, was significantly exacerbated in SerpinC1(+/-) rats compared to wild-type littermates. Concomitantly, renal oxidative stress, tubular apoptosis, and macrophage infiltration following this injury were significantly aggravated in SerpinC1(+/-) rats. However, significant thrombosis was not found in the kidneys of any group of rats. Antithrombin III is reported to stimulate the production of prostaglandin I2, a known regulator of renal cortical blood flow, in addition to having anti-inflammatory effects and to protect against renal failure. Prostaglandin F1α, an assayable metabolite of prostaglandin I2, was increased in the kidneys of the wild-type rats at 3 h after reperfusion. The increase of prostaglandin F1α was significantly blunted in SerpinC1(+/-) rats, which preceded increased tubular injury and oxidative stress. Thus, our study found a novel role of SerpinC1 insufficiency in increasing the severity of renal ischemia/reperfusion injury.

材料
產品編號
品牌
產品描述

Sigma-Aldrich
单克隆抗 β-肌动蛋白抗体 小鼠抗, clone AC-15, ascites fluid
Sigma-Aldrich
抗-小鼠IgG(全分子)–过氧化物酶 绵羊抗, affinity isolated antibody, buffered aqueous solution
Sigma-Aldrich
抗凝血酶 III 来源于人类血浆, ≥95% (SDS-PAGE)